Eli Lilly (LLY) and Novo Nordisk (NVO) have entered into a partnership with Mangoceuticals (MGRX) to launch two integrated programs that provide direct access to the two firms' GLP-1 medications, Mangoceuticals said Thursday.

MangoRx Direct and PeachesRx Direct will provide access to Lilly's Zepbound and Novo Nordisk's Wegovy, respectively, Mangoceuticals said.

Through MangoRx and PeachesRx's secure telehealth platform, customers will receive virtual consultations with board-certified providers, personalized weight management treatment plans, ongoing clinical monitoring and support, and fulfillment of the medications, the company said.